首次引入儿童用药品及罕见病药品市场独占期新版《药品管理法实施条例》正式发布

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" marks the first comprehensive revision in 23 years, aimed at enhancing the drug regulatory system and supporting high-quality development in the pharmaceutical industry. The regulations will take effect on May 15, 2026 [1]. Group 1: Regulatory Changes - Over 90% of the provisions in the revised regulations have been amended, shifting the regulatory focus from drug production and operation enterprises to drug marketing authorization holders, who are now required to establish robust quality assurance and pharmacovigilance systems [1][2]. - The regulations introduce a market exclusivity period for pediatric and rare disease medications, incentivizing innovation in special drug development to better meet clinical needs [2][3]. Group 2: Innovation and Market Exclusivity - The regulations provide a market exclusivity period of up to 2 years for new pediatric drugs and up to 7 years for rare disease treatments, contingent on the marketing authorization holder's commitment to ensure drug supply [2][3]. - This exclusivity is designed to encourage investment in biotechnology companies focused on rare diseases, preventing resource wastage and promoting differentiated competition in the market [3]. Group 3: Protection of Intellectual Property - The regulations strengthen the protection of innovators' rights by safeguarding undisclosed trial data and other information submitted by marketing authorization holders for up to 6 years, preventing unauthorized commercial use [4]. - The State Drug Administration plans to enhance drug regulatory reforms, support innovation, and improve the efficiency of drug review and approval processes to accelerate the availability of new drugs that meet public demand [4].